Banka BioLoo Q2 FY27 Profit Returns Despite Revenue Decline

Banka BioLoo Limited returned to a consolidated net profit of ₹0.13 crore in Q2 FY27, compared with a ₹1.09 crore loss a year earlier, although revenue from operations declined 9.6% year on year to ₹11.76 crore.

How did Banka BioLoo perform in Q2 FY27?

Banka BioLoo reported consolidated revenue from operations of ₹11.76 crore for the September 2026 quarter, up 11.5% from ₹10.55 crore in Q1 FY27 but below ₹13.01 crore in Q2 FY26. Total income rose sequentially by 11.4% to ₹11.87 crore, while it was 9.2% lower than the year-earlier quarter.

The company recorded a consolidated net profit of ₹0.13 crore, reversing losses of ₹0.04 crore in the preceding quarter and ₹1.09 crore a year earlier. Profit before tax was ₹0.18 crore, compared with a pre-tax loss of ₹0.09 crore in Q1 FY27 and a loss of ₹1.59 crore in Q2 FY26. Earnings per share stood at ₹0.12, against negative ₹0.01 in the previous quarter and negative ₹1.00 a year earlier.

What drove the improvement in profitability?

Banka BioLoo's reported total expenses fell 20.3% year on year to ₹11.68 crore in Q2 FY27, from ₹14.65 crore in Q2 FY26. Expenses were 8.7% higher than the ₹10.74 crore reported in Q1 FY27, but this increase was lower than the sequential growth in total income.

The resulting operating margin improved to 19.4%, from 17.2% in the June quarter and negative 0.1% a year earlier. The net margin moved to 1.1%, versus negative 0.4% sequentially and negative 8.4% in Q2 FY26. Other income was ₹0.10 crore, broadly stable from Q1 FY27 and more than double the ₹0.05 crore recorded in the corresponding quarter last year.

Why do the standalone and consolidated results differ?

Banka BioLoo also disclosed stronger standalone figures for Q2 FY27. Standalone revenue was ₹16.52 crore, up 24.7% from ₹13.25 crore in Q2 FY26, while total income increased 24.5% to ₹16.56 crore. Standalone net profit was ₹0.42 crore, reversing a ₹1.10 crore loss a year earlier.

Standalone EBITDA was ₹1.53 crore, with a 9.3% margin, compared with an EBITDA loss of ₹0.45 crore in Q2 FY26. Standalone profit before tax was ₹0.50 crore, against a loss of ₹1.52 crore a year earlier. The reported standalone and consolidated results represent different reporting bases, and investors should compare each set of figures on a like-for-like basis.

What does the first-half performance show?

Banka BioLoo reported consolidated revenue of ₹22.31 crore for the first half of FY27, which was 7.6% lower year on year. Consolidated profit for the half year was ₹0.09 crore, compared with a loss in the prior-year period, indicating that the September-quarter profit followed a weak June-quarter result.

The company spent ₹11.79 crore on plant and equipment during the first half and raised borrowings, according to the disclosed financial information. Its auditors also flagged ₹7.71 crore of government receivables for which no provision had been made. These items are relevant for assessing the company's balance-sheet position, cash requirements and the eventual collection of receivables.

What are the operational indicators investors should track?

Banka BioLoo reported an unexecuted order book of ₹83.4 crore as of September 30, 2026. It also said it secured ₹16 crore of new orders during Q2 FY27, with private clients accounting for all of these bookings. The order book provides disclosed visibility into work yet to be executed, but its conversion into revenue depends on project execution.

The share price was reported at ₹78.95 after the results announcement, down 4.99%. The market reaction came as the company delivered a quarterly profit and better margins but recorded lower consolidated revenue than a year earlier. For investors, subsequent filings on revenue execution, borrowings, capital expenditure and government receivable collections remain important indicators.

Conclusion

Banka BioLoo's Q2 FY27 consolidated results show a return to profitability, supported by a sharp improvement in operating and net margins. Yet the 9.6% decline in year-on-year revenue and the modest ₹0.13 crore consolidated profit show that the earnings recovery remains limited at the consolidated level.

The next disclosures to watch are progress in executing the ₹83.4 crore order book, the effect of first-half capital expenditure and borrowings, and developments in the ₹7.71 crore government receivables identified by the auditors. Revenue growth in the following quarters will indicate whether improved margins can be sustained alongside higher business volumes.